News|Videos|March 2, 2026

6 Hepatology Headlines You Missed in February 2026

Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.

February 2026 spotlighted a wave of innovation in genetic and translational hepatology, particularly in alpha-1 antitrypsin deficiency (AATD). Interim data for YOLT-202 demonstrated that a single in vivo base-editing dose could meaningfully increase functional AAT levels, while TSRA-196 earned both Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA), reinforcing growing regulatory support for one-time gene-editing strategies aimed at correcting the underlying PiZZ mutation.